#China #Hong Kong #DAXXIFY #Sisram Medical #Neuromodulator

Sisram Medical's Milestone Achievement for DAXXIFY

Sisram Medical Ltd, a prominent player in the global wellness industry, has recently achieved a significant milestone with the completion of quality testing for its product DAXXIFY by the National Institutes for Food and Drug Control (NIFDC) in China. This successful testing is crucial as it confirms that DAXXIFY meets the high standards of quality, safety, and efficacy required by Chinese regulations, marking a major step towards its anticipated market launch.

DAXXIFY, which is trademarked as 达希斐® in mainland China, is distinguished as the world’s first long-acting neuromodulator formulated with peptides. It utilizes botulinum toxin type A (DaxibotulinumtoxinA) as its active ingredient and is uniquely formulated with Peptide Exchange Technology (PXT). This innovation aims to deliver prolonged effects with a rapid onset, addressing the temporary improvement of moderate to severe glabellar lines, which are wrinkles produced from muscle activity around the forehead area in adults.

In terms of commercial readiness, Sisram has had initial orders from key medical aesthetic institutions, reflecting strong market interest and readiness for DAXXIFY. As the company transitions its operations from preparation to the sales phase, it is not just capitalizing on a new product but is also expanding its overall portfolio in the medical aesthetics market.

To support DAXXIFY's rollout, Sisram has assembled a robust professional team dedicated to market expansion, clinical support, and supply chain management. This team comprises seasoned professionals who are working on reinforcing its presence within the medical aesthetics community. Additionally, Sisram has established strategic partnerships with respected industry leaders such as Fosun Wanbang and Shanghai Pharmaceuticals. These collaborations are designed to maintain a dependable and traceable supply chain that emphasizes quality at every stage, from manufacturing to clinical application.

The company's commitment to quality and effectiveness positions DAXXIFY as a standout option for consumers in China, where the demand for premium medical aesthetic solutions is surging. As the first injectable product of its kind in the region, DAXXIFY is anticipated to elevate standards in the industry and provide an exceptional aesthetic experience to consumers.

Furthermore, by introducing DAXXIFY, Sisram is not only introducing a new product but is also paving a pathway towards a second growth curve for the company. The launch aligns with Sisram’s strategy to strengthen its injectables segment while contributing to a wider ecosystem of wellness solutions that includes energy-based devices (EBD), diagnostics, and other aesthetic interventions.

As expectations build around the imminent availability of DAXXIFY in clinical settings, Sisram Medical is diligently preparing its operations to ensure that both healthcare professionals and consumers can benefit from the pioneering effects of this innovative neuromodulator. The company recognizes the importance of standardized and precise treatment protocols, which will be facilitated through systematic training programs for physicians, offering them the tools needed to maximize treatment outcomes for patients.

With DAXXIFY set to hit the market soon, Sisram's stakeholders, partners, and the broader medical community remain optimistic about the implications for enhancing aesthetic treatments across mainland China. The company is committed to delivering diverse, reliable wellness solutions, solidifying its position as a leader in the medical aesthetics field, and preparing to meet evolving consumer demands with DAXXIFY.